TREATING DEADLY INFLAMMATION
CytoSorb® is a unique blood purification therapy to control deadly inflammation in life threatening illnesses in the ICU and cardiac surgery. The product is currently approved in the European Union and distributed in 43 countries around the world.
THE POWER OF THE BEAD
Powered by massive surface area, our purification technologies are based on biocompatible, highly porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption.
INFORMATION FOR INVESTORS
CytoSorbents is a leader in critical care immunotherapy. The company is committed to serving the best interests of our patients and their families, our customers, our employees, and our shareholders.
Register for the 19th Annual B. Riley FBR Investor Conference Webcast click here